EVOLUS, INC. Research and Development Expense
EVOLUS, INC. (EOLS) reported Research and Development Expense of $468.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-10
- EVOLUS, INC. research and development expense for the quarter ending 2022-03-31 was $468.00K, a 44.35% decline year-over-year.
- EVOLUS, INC. research and development expense for the quarter ending 2021-12-31 was $423.00K, a 41.17% decline year-over-year.
- EVOLUS, INC. research and development expense for the quarter ending 2021-09-30 was $301.00K, a 14.00% decline year-over-year.
- EVOLUS, INC. research and development expense for the quarter ending 2021-06-30 was $499.00K, a 244.14% increase year-over-year.
- EVOLUS, INC. research and development expense for fiscal 2021 was $2.06M, a 19.86% increase from fiscal 2020.
- EVOLUS, INC. research and development expense for fiscal 2020 was $1.72M, a 56.66% decline from fiscal 2019.
- EVOLUS, INC. research and development expense for fiscal 2019 was $3.97M, a 38.75% decline from fiscal 2018.
- EVOLUS, INC. research and development expense for fiscal 2018 was $6.49M, a 3.02% decline from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $468.00K 10-Q · filed 2022-05-10 | $891.00K derived: sum of 2 quarters · filed 2022-05-10 | $1.19M derived: sum of 3 quarters · filed 2022-05-10 | $1.69M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-12-31 | $423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $724.00K derived: sum of 2 quarters · filed 2022-03-03 | $1.22M derived: sum of 3 quarters · filed 2022-03-03 | $2.06M 10-K · filed 2022-03-03 |
| 2021-09-30 | $301.00K 10-Q · filed 2021-11-02 | $800.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.64M 10-Q · filed 2021-11-02 | $2.36M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-06-30 | $499.00K 10-Q · filed 2021-08-04 | $1.34M 10-Q · filed 2021-08-04 | $2.06M derived: sum of 3 quarters · filed 2022-05-10 | $2.41M derived: sum of 4 quarters · filed 2022-05-10 |
| 2021-03-31 | $841.00K 10-Q · filed 2022-05-10 | $1.56M derived: sum of 2 quarters · filed 2022-05-10 | $1.91M derived: sum of 3 quarters · filed 2022-05-10 | $2.06M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $719.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.07M derived: sum of 2 quarters · filed 2022-03-03 | $1.21M derived: sum of 3 quarters · filed 2022-03-03 | $1.72M 10-K · filed 2022-03-03 |
| 2020-09-30 | $350.00K 10-Q · filed 2021-11-02 | $495.00K derived: sum of 2 quarters · filed 2021-11-02 | $1.00M 10-Q · filed 2021-11-02 | $1.42M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $145.00K 10-Q · filed 2021-08-04 | $653.00K 10-Q · filed 2021-08-04 | $1.07M derived: sum of 3 quarters · filed 2021-08-04 | $1.76M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $507.00K 10-Q · filed 2021-05-12 | $925.00K derived: sum of 2 quarters · filed 2021-05-12 | $1.62M derived: sum of 3 quarters · filed 2021-05-12 | $2.13M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.11M derived: sum of 2 quarters · filed 2021-03-25 | $1.62M derived: sum of 3 quarters · filed 2021-03-25 | $3.97M 10-K · filed 2021-03-25 |
| 2019-09-30 | $693.00K 10-Q · filed 2020-10-29 | $1.20M derived: sum of 2 quarters · filed 2020-10-29 | $3.56M 10-Q · filed 2020-10-29 | $4.74M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $509.00K 10-Q · filed 2020-08-10 | $2.86M 10-Q · filed 2020-08-10 | $4.05M derived: sum of 3 quarters · filed 2020-08-10 | $6.02M derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $2.35M 10-Q · filed 2020-05-11 | $3.54M derived: sum of 2 quarters · filed 2020-05-11 | $5.51M derived: sum of 3 quarters · filed 2020-05-11 | $7.16M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $3.16M derived: sum of 2 quarters · filed 2020-02-25 | $4.81M derived: sum of 3 quarters · filed 2020-02-25 | $6.49M 10-K · filed 2020-02-25 |
| 2018-09-30 | $1.98M 10-Q · filed 2019-11-04 | $3.63M derived: sum of 2 quarters · filed 2019-11-04 | $5.30M 10-Q · filed 2019-11-04 | $6.51M derived: sum of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | $1.65M 10-Q · filed 2019-08-12 | $3.33M 10-Q · filed 2019-08-12 | $4.53M derived: sum of 3 quarters · filed 2019-08-12 | $6.00M derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | $1.68M 10-Q · filed 2019-05-01 | $2.89M derived: sum of 2 quarters · filed 2019-05-01 | $4.35M derived: sum of 3 quarters · filed 2019-05-01 | $5.72M derived: sum of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | $2.67M derived: sum of 2 quarters · filed 2019-03-20 | $4.04M derived: sum of 3 quarters · filed 2019-03-20 | $6.69M 10-K · filed 2019-03-20 |
| 2017-09-30 | $1.47M 10-Q · filed 2018-11-05 | $2.83M derived: sum of 2 quarters · filed 2018-11-05 | $5.48M 10-Q · filed 2018-11-05 | |
| 2017-06-30 | $1.36M 10-Q · filed 2018-08-02 | $4.02M 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | $2.65M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |